宫颈癌组织中miR-183与GSPT1的表达及临床意义

临床肿瘤学杂志 ›› 2022, Vol. 27 ›› Issue (03): 210-214.

宫颈癌组织中miR-183与GSPT1的表达及临床意义

1 570203 海口海口市妇幼保健院病理科 2 570203 海口市妇幼保健院检验科 3 570203 海口市妇幼保健院妇产科

收稿日期:2021-09-24 修回日期:2022-02-09 出版日期:2022-03-25 发布日期:2022-05-12

The expression and clinical significance of miR-183 and GSPT1 in cervical cancer

Department of Pathology, Haikou Maternal and Child Health Care Hospital, Haikou 570203，China

Received:2021-09-24 Revised:2022-02-09 Online:2022-03-25 Published:2022-05-12

摘要/Abstract

摘要： 目的探讨宫颈癌组织中微小RNA (miR)-183与细胞周期G1到S期的转换1 (GSPT1)的表达及与预后的关系。方法收集2014年1月至2016年12月接受根治性手术的91例宫颈癌患者。采用实时荧光定量PCR检测91例宫颈癌和癌旁组织中miR-183和GSPT1的表达。分析宫颈癌组织中miR-183与GSPT1表达的相关性，并采用生物信息学方法预测两者之间的结合位点。进一步分析miR-183和GSPT1表达与宫颈癌临床病理特征及预后的关系。结果宫颈癌组织中miR-183的表达（0.521±0.065）低于癌旁组织（1.241±0.286），差异有统计学意义（P=0.000）。宫颈癌组织中GSPT1的表达（2.034±0.374）高于癌旁组织（0.708±0.157），差异有统计学意义（P=0.000）。宫颈癌组织中miR-183与GSPT1的表达呈负相关（r=-0.621，P=0.001）。生物信息学预测结果显示，GSPT1 mRNA第981至987碱基存在与miR-183相互作用的位点。宫颈癌组织中miR-183和GSPT1表达与FIGO分期、分化程度、肌层浸润和淋巴结转移有关（P＜0.05），与年龄和病理类型无关（P>0.05）。全组1、3、5年无病生存率分别为86.8%、73.6%和61.5%。miR-183高表达组1、3、5年无病生存率分别为91.1%、86.6%和80.0%，优于miR-183低表达组的82.6%、60.9%和43.5%，差异有统计学意义（P=0.012）。GSPT1高表达组1、3、5年无病生存率分别为86.0%、60.4%和39.5%，低于GSPT1低表达组的87.5%、85.4%和81.2%，差异有统计学意义（P=0.007）。结论宫颈癌组织中miR183表达降低，GSPT1表达升高，两者共同促进宫颈癌进展，有望成为宫颈癌预后评估的标志物。

关键词: 宫颈癌, 微小RNA-183, 细胞周期G1到S期的转换1, 预后

Abstract: Objective To explore the expression and clinical value of microRNA (micro RNA, miR)-183 and cell cycle G1 to S phase transition 1 (GSPT1) in cervical cancer. Methods From January 2014 to December 2016，91 patients with cervical cancer who were surgically treated were enrolled. Fluorescence quantitative PCR was used to detect the expression of miR183 and GSPT1 in 91 cases of cervical cancer and adjacent tissues. The correlation between the expression of miR-183 and GSPT1 in cancer tissues were analyzed by linear correlation analysis. Bioinformatics was used to predict the site of interaction between the two. The relationship of miR-183, GSPT1 expression with clinicopathological parameters as well as prognosis were statistically analyzed. Results The expression of miR183 in cancer tissues (0.521±0.065) was lower than that in adjacent tissues (1.241±0.286), and the difference was statistically significant (P=0.000); the expression of GSPT1 in cancer tissues (2.034±0.374) was significantly higher than that in adjacent tissues (0.708±0.157) , and the difference was statistically significant (P=0.000). There was a significant negative correlation between the expression of miR-183 and GSPT1 in cancer tissues (r=-0.621, P=0.001). Bioinformatics predicted that GSPT1 mRNA between base 981 to 987 had an interaction site with miR-183.The expression of miR-183 and GSPT1 was related to FIGO stages, tumor differentiation, depth of muscle invasion and lymph node metastasis (P<0.05), but not with pathological types and age (P>0.05). The 1-, 3-, and 5-year disease-free survival rates of 91 cervical cancer patients were 86.8%, 73.6% and 61.5%, respectively. The 1-, 3- and 5-year disease-free survival rates in the high miR-183 expression group were 91.1%, 86.6% and 80.0% respectively, which were better than 82.6%, 60.9% and 43.5% in the low miR-183 expression group (P=0.012). The 1-, 3- and 5-year diseasefree survival rates in the high GSPT1 expression group were 86.0%, 60.4% and 39.5%, respectively, lower than 87.5%, 85.4% and 81.2% in the low GSPT1 expression group (P=0.007). Conclusion The expression of miR-183 in cervical cancer is decreased, and the expression of GSPT1 is increased. The two promotes the tumor progression of cervical cancer, which are expected to be prognostic markers for cervical cancer.

Key words: Cervical cancer, MicroRNA-183, Cell cycle G1 to S phase transition 1, Prognosis

柯艺文, 陈绵平, 张馨, 庞春玉, 史春. 宫颈癌组织中miR-183与GSPT1的表达及临床意义[J]. 临床肿瘤学杂志, 2022, 27(03): 210-214.

KE Yiwen, CHEN Mianping, ZHANG Xin, PANG Chunyu, SHI Chun.. The expression and clinical significance of miR-183 and GSPT1 in cervical cancer[J]. Chinese Clinical Oncology, 2022, 27(03): 210-214.

参考文献

Metrics

Viewed

Full text

Abstract

Cited

Shared

Discussed

本文评价

推荐阅读 10

[1]	许景艳¹，欧阳建^１，章宜芬²，周荣富¹，陈　兵¹，张启国¹，杨永公¹，邵小雁¹，徐　勇¹，关朝阳¹. 原发性肋骨血管肉瘤的诊治探讨[J]. 临床肿瘤学杂志, 2009, 14(1): 70 .
[2]	徐晓明¹，唐金海¹，刘万花²，郑凯尔²，秦建伟¹，赵祥生¹，张　彤³. 触诊阴性乳腺癌的定位方法与同期手术治疗[J]. 临床肿瘤学杂志, 2009, 14(1): 43 .
[3]	战怀兵^１，蔡曦光^１，吴凤铭^２. Ｂｍi-１和ｈＴＥＲＴ在非小细胞肺癌中的表达及相关性研究[J]. 临床肿瘤学杂志, 2009, 14(1): 10 .
[4]	朱　芳，李振宇，任精华，伍　钢，彭　纲. ＶＥＧＦ与肿瘤血管生成拟态关系的研究[J]. 临床肿瘤学杂志, 2009, 14(1): 20 .
[5]	刘秀峰，秦叔逵，钱　军，王　琳，杨宁蓉，刘静冰，华海清. 重组人血管内皮抑制素和参一胶囊联合化疗药物治疗胚胎性横纹肌肉瘤[J]. 临床肿瘤学杂志, 2009, 14(1): 63 .
[6]	黄培钰¹，汪　波²，张　星³，洪明晃¹，吴　烜⁴，陈明远¹，张　力^1，4. 组织芯片技术分析ｃ-ｋｉｔ蛋白在鼻咽癌组织中的表达及其临床意义[J]. 临床肿瘤学杂志, 2009, 14(2): 97 .
[7]	陈德玉¹，方　娜²，华　晔¹. ＰＴＴＧ和ｐ５３在非小细胞肺癌中的表达及其意义[J]. 临床肿瘤学杂志, 2009, 14(2): 127 .
[8]	王　轩，陆　雷，华长江，江　涛，李增才，张　斌，刘现忠，许正昌. 原位肝移植治疗原发性肝癌６８例报告[J]. 临床肿瘤学杂志, 2009, 14(2): 147 .
[9]	周　晔¹，冯　虹¹. 促血管生成素１、２及Ｔｉｅ２受体ｍＲＮＡ在卵巢上皮性浆液性腺癌中的表达[J]. 临床肿瘤学杂志, 2009, 14(2): 144 .
[10]	王轶楠¹，李红民²，赵　郁¹，刘卫东¹，马守东¹，岳海书¹. 细胞毒分子在原发结内的外周Ｔ细胞淋巴瘤非特指型中的表达及意义[J]. 临床肿瘤学杂志, 2009, 14(2): 106 .